Christian Nitsche
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Christian Nitsche has a total of 482 co-authors. Here are the top co-authors by number of shared publications:
- Andreas Anselm Kammerlander
Division of Cardiology, Department of Internal Medicine II, Medical University of Vienna, 1090 Vienna, Austria
41 shared publications - Christian Hengstenberg
Department of Internal Medicine II, Division of Cardiology, Medical University of Vienna, 1090 Vienna, Austria
32 shared publications - Julia Mascherbauer
Department of Internal Medicine 3, University Hospital St. Pölten-NOE LGA, Karl Landsteiner University, 3100 St. Pölten, Austria
26 shared publications Christian Hengstenberg
Medical University of Vienna
25 shared publications- Matthias Koschutnik
Division of Cardiology, Department of Internal Medicine II, Medical University of Vienna, 1090 Vienna, Austria
24 shared publications - Carolina Donà
Division of Cardiology, Department of Internal Medicine II, Medical University of Vienna, 1090 Vienna, Austria
22 shared publications
Latest Publications
- 13 October 2026
- Published by Wolters Kluwer Health in Circulation
Definition and Prognosis of Mitral Regurgitation in Transthyretin Amyloid Cardiomyopathy: A Multicenter International Cohort Study
BACKGROUND: In transthyretin amyloid cardiomyopathy, mitral regurgitation (MR) severity may be underestimated by conventional (semi-)quantitative echocardiographic criteria due to restrictive low-flow hemodynamics. We sought to define and validate disease-specific MR risk thresholds and compare their prognostic performance with guideline definitions. METHODS: In a multicenter cohort study (8 centers, 4 countries), 1101 patients with newly diagnosed transthyretin amyloid cardiomyopathy (derivation, n=722; validation, n=379) underwent standardized echocardiography with blinded core laboratory analysis, including MR measures (vena contracta width, effective regurgitant orifice area, regurgitant volume, and regurgitant fraction). All-cause mortality and time to first heart failure hospitalization (HFH) served as end points. Prognostic thresholds were derived from spline analysis, validated externally, and compared with American Heart Association/American College of Cardiology, European Society of Cardiology/European Association for Cardiothoracic Surgery, and American Society of Echocardiography definitions. RESULTS: During a median follow-up of 24.9 months (interquartile range, 12.0–42.0), 314 patients (28.5%) died and 244 (22.2%) experienced HFH. All MR metrics independently predicted mortality and HFH (all P 0.25 cm 2 , regurgitant volume >38 mL, and regurgitant fraction >35%. Compared with guideline grading (≈12%–13%), the composite MR grading scheme classified a significantly higher proportion (21%) as severe MR and provided superior discrimination for clinical outcomes at 12 and 24 months in both the derivation and validation cohort. After multivariable adjustment, only the composite MR grading scheme remained strongly predictive for both mortality (hazard ratio, 1.20 [1.07–1.36]) and HFH (hazard ratio, 1.21 [1.05–1.38]). CONCLUSIONS: Quantitative MR thresholds in transthyretin amyloid cardiomyopathy are substantially lower than current guideline cutoffs. A validated, risk-based composite MR grading scheme improves prediction of both mortality and HFH, better reflecting the restrictive low-flow pathophysiology of transthyretin amyloid cardiomyopathy and supporting disease-specific MR grading. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT06836011.
- 13 October 2026
- Published by Wolters Kluwer Health in Circulation
Definition and Prognosis of Mitral Regurgitation in Transthyretin Amyloid Cardiomyopathy: A Multicenter International Cohort Study
BACKGROUND: In transthyretin amyloid cardiomyopathy, mitral regurgitation (MR) severity may be underestimated by conventional (semi-)quantitative echocardiographic criteria due to restrictive low-flow hemodynamics. We sought to define and validate disease-specific MR risk thresholds and compare their prognostic performance with guideline definitions. METHODS: In a multicenter cohort study (8 centers, 4 countries), 1101 patients with newly diagnosed transthyretin amyloid cardiomyopathy (derivation, n=722; validation, n=379) underwent standardized echocardiography with blinded core laboratory analysis, including MR measures (vena contracta width, effective regurgitant orifice area, regurgitant volume, and regurgitant fraction). All-cause mortality and time to first heart failure hospitalization (HFH) served as end points. Prognostic thresholds were derived from spline analysis, validated externally, and compared with American Heart Association/American College of Cardiology, European Society of Cardiology/European Association for Cardiothoracic Surgery, and American Society of Echocardiography definitions. RESULTS: During a median follow-up of 24.9 months (interquartile range, 12.0–42.0), 314 patients (28.5%) died and 244 (22.2%) experienced HFH. All MR metrics independently predicted mortality and HFH (all P 0.25 cm 2 , regurgitant volume >38 mL, and regurgitant fraction >35%. Compared with guideline grading (≈12%–13%), the composite MR grading scheme classified a significantly higher proportion (21%) as severe MR and provided superior discrimination for clinical outcomes at 12 and 24 months in both the derivation and validation cohort. After multivariable adjustment, only the composite MR grading scheme remained strongly predictive for both mortality (hazard ratio, 1.20 [1.07–1.36]) and HFH (hazard ratio, 1.21 [1.05–1.38]). CONCLUSIONS: Quantitative MR thresholds in transthyretin amyloid cardiomyopathy are substantially lower than current guideline cutoffs. A validated, risk-based composite MR grading scheme improves prediction of both mortality and HFH, better reflecting the restrictive low-flow pathophysiology of transthyretin amyloid cardiomyopathy and supporting disease-specific MR grading. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT06836011.
- Open Access
- 8 October 2026
- Published by Public Library of Science (PLoS) in PLOS Digital Health
- Vol. 5 (10) , e0001637
Screening for patients at risk for cardiac amyloidosis via electronic health records: A multicenter machine learning development and validation study
Timely detection is crucial to improve outcomes in patients with cardiac amyloidosis (CA) by initiation of guideline-directed disease-modifying treatments. Although confirmatory bone scintigraphy is highly accurate for CA detection, identifying at-risk patients for referral remains challenging. This study aimed to develop and validate a machine learning model, Amylo-Detect , using structured multimodal electronic health record (EHR) data to guide referrals for confirmatory scintigraphy and monoclonal protein testing. Consecutive all-comer patients (n = 11,616) referred for bone scintigraphy at the Vienna General Hospital (2010–2023) were retrospectively included. Patients referred before August 2020 formed the development cohort. The remaining patients comprised the internal validation cohort. External validation was performed at the University Hospital Essen (n = 1,521). Amylo-Detect was trained using 50 routinely available parameters to predict CA-suggestive uptake (Perugini grade ≥2) and compared with an existing score and clinical routine. High-grade uptake was present in 388 patients (3.0%). Amylo-Detect demonstrated excellent performance in development (AUC 0.93), independent internal validation (AUC 0.91), and external validation cohort (AUC 0.91), outperforming existing scoring systems and clinical routine. Results were consistent across subgroups, even when crucial predictors were missing. Of the 42/388 (10.8%) patients missed in clinical routine, 12/42 (29%) were additionally detected by Amylo-Detect . The model further conveyed significant prognostic value for mortality and heart failure hospitalization. We present Amylo-Detect , a validated EHR-based tool for CA risk prediction, available as a web app, allowing application and further evaluation. By improving timely detection and referral, Amylo-Detect may help address diagnostic delays, pending prospective evaluation.
- 8 October 2026
- Published by Public Library of Science (PLoS) in PLOS Digital Health
- Vol. 5 (10) , e0001637
Open AccessScreening for patients at risk for cardiac amyloidosis via electronic health records: A multicenter machine learning development and validation study
Timely detection is crucial to improve outcomes in patients with cardiac amyloidosis (CA) by initiation of guideline-directed disease-modifying treatments. Although confirmatory bone scintigraphy is highly accurate for CA detection, identifying at-risk patients for referral remains challenging. This study aimed to develop and validate a machine learning model, Amylo-Detect , using structured multimodal electronic health record (EHR) data to guide referrals for confirmatory scintigraphy and monoclonal protein testing. Consecutive all-comer patients (n = 11,616) referred for bone scintigraphy at the Vienna General Hospital (2010–2023) were retrospectively included. Patients referred before August 2020 formed the development cohort. The remaining patients comprised the internal validation cohort. External validation was performed at the University Hospital Essen (n = 1,521). Amylo-Detect was trained using 50 routinely available parameters to predict CA-suggestive uptake (Perugini grade ≥2) and compared with an existing score and clinical routine. High-grade uptake was present in 388 patients (3.0%). Amylo-Detect demonstrated excellent performance in development (AUC 0.93), independent internal validation (AUC 0.91), and external validation cohort (AUC 0.91), outperforming existing scoring systems and clinical routine. Results were consistent across subgroups, even when crucial predictors were missing. Of the 42/388 (10.8%) patients missed in clinical routine, 12/42 (29%) were additionally detected by Amylo-Detect . The model further conveyed significant prognostic value for mortality and heart failure hospitalization. We present Amylo-Detect , a validated EHR-based tool for CA risk prediction, available as a web app, allowing application and further evaluation. By improving timely detection and referral, Amylo-Detect may help address diagnostic delays, pending prospective evaluation.
- Open Access
- 30 July 2026
- Published by Springer Nature in Heart Failure Reviews
- Vol. 31 (1) , 89
Myocardial remodeling in valvular heart disease: pathophysiology, multimodality imaging and treatment implications
Valvular cardiomyopathy has emerged as a key concept linking valvular heart disease (VHD) with myocardial remodeling and the development of heart failure (HF). This state-of-the-art review provides a comprehensive overview of pathophysiological mechanisms, multimodality imaging, and implication for valve interventions across the spectrum of VHD. We systematically address HF in the context of aortic valve disease, including aortic stenosis and aortic regurgitation, mitral valve disease with a particular focus on mitral regurgitation, and tricuspid valve regurgitation. For each valvular lesion, we integrate evidence on pathophysiological mechanisms on myocardial (mal)adaptation leading to myocardial fibrosis and ultimately HF and death. Additionally, we highlight the role of multimodality imaging for early detection of myocardial remodeling and discuss implications for patient selection and timing of valve interventions. Beyond single-valve disease, we further explore the complex interplay of multiple and mixed valvular heart disease and review emerging data on the interaction between VHD and cardiac amyloidosis, an increasingly recognized and clinically relevant overlap. Overall, this state-of-the-art review underscores that outcomes in VHD are not solely determined by severity of valvular lesions but critically depend on the extent of associated myocardial damage. A deeper understanding of valvular cardiomyopathy may improve risk stratification, refine patient selection, and support the implementation of tailored therapeutic strategies.
- 30 July 2026
- Published by Springer Nature in Heart Failure Reviews
- Vol. 31 (1) , 89
Open AccessMyocardial remodeling in valvular heart disease: pathophysiology, multimodality imaging and treatment implications
Valvular cardiomyopathy has emerged as a key concept linking valvular heart disease (VHD) with myocardial remodeling and the development of heart failure (HF). This state-of-the-art review provides a comprehensive overview of pathophysiological mechanisms, multimodality imaging, and implication for valve interventions across the spectrum of VHD. We systematically address HF in the context of aortic valve disease, including aortic stenosis and aortic regurgitation, mitral valve disease with a particular focus on mitral regurgitation, and tricuspid valve regurgitation. For each valvular lesion, we integrate evidence on pathophysiological mechanisms on myocardial (mal)adaptation leading to myocardial fibrosis and ultimately HF and death. Additionally, we highlight the role of multimodality imaging for early detection of myocardial remodeling and discuss implications for patient selection and timing of valve interventions. Beyond single-valve disease, we further explore the complex interplay of multiple and mixed valvular heart disease and review emerging data on the interaction between VHD and cardiac amyloidosis, an increasingly recognized and clinically relevant overlap. Overall, this state-of-the-art review underscores that outcomes in VHD are not solely determined by severity of valvular lesions but critically depend on the extent of associated myocardial damage. A deeper understanding of valvular cardiomyopathy may improve risk stratification, refine patient selection, and support the implementation of tailored therapeutic strategies.
- Open Access
- 6 July 2026
- Published by Oxford University Press (OUP) in European Heart Journal - Valvular and Structural Heart Disease
- Vol. 2 (3)
Preventing ‘dock drop’ during transcatheter mitral valve replacement with the SAPIEN M3 system
- 6 July 2026
- Published by Oxford University Press (OUP) in European Heart Journal - Valvular and Structural Heart Disease
- Vol. 2 (3)
Open AccessPreventing ‘dock drop’ during transcatheter mitral valve replacement with the SAPIEN M3 system
- Open Access
Deep Clinical Phenotyping of Perugini Grade 1 on Bone Scintigraphy: An Imaging-Phenotype Association Study
Purpose: A planar Perugini grade 1 scan is equivocal for transthyretin amyloid cardiomyopathy (ATTR-CM), has no dedicated management pathway and is biologically heterogeneous, spanning early or low-burden ATTR, AL amyloidosis and non-amyloid blood-pool activity. Rather than investigating grade 1 as a step toward amyloid confirmation, we characterized the clinical phenotype it marks and tested whether that phenotype, rather than amyloid, drives its prognosis. Methods: We studied 9,170 consecutive patients who underwent [ 99m Tc]Tc-DPD bone scintigraphy between 2010 and 2020, graded on planar imaging by blinded expert consensus. Using an imaging-phenotype association (IPA) framework analogous to genome-wide association analysis, we related Perugini grade to 1,243 clinical, laboratory, echocardiographic, cardiac magnetic resonance and ICD-10 comorbidity variables from electronic health records, adjusting for age, sex and cancer history. The outcome was a composite of heart failure hospitalization or death. Results: Grade 1 occurred in 175 (1.9%) and grade ≥2 in 142 (1.6%) patients. Grade ≥2 reproduced the canonical infiltrative ATTR phenotype, with greater septal thickness, higher extracellular volume, neuropathy and atrial fibrillation, validating the framework. Grade 1 instead marked a non-infiltrative cardiometabolic phenotype dominated by hypertension, chronic ischemic heart disease, high BMI, anemia, reduced eGFR and atrial enlargement, with low extracellular volume and septal thickness arguing against meaningful infiltration. Grade 1 carried worse outcomes than grade 0 (adjusted HR 1.30, 95% CI 1.07 to 1.59). Within grade 1, a cardiometabolic phenotype defined by hypertension, high BMI and low hematocrit, with or without chronic ischemic heart disease, identified patients whose risk matched or exceeded that of grade ≥2 (median HR 2.46 versus HR 1.76), indicating that grade 1 prognosis is driven substantially by comorbid cardiometabolic disease rather than amyloid burden. Conclusions: Perugini grade 1 is neither uniform early amyloid nor a benign artifact but a mixed-etiology, predominantly non-infiltrative cardiometabolic phenotype that carries clinically meaningful risk. A simple cardiometabolic phenotype stratifies this risk, supporting reinterpretation of grade 1 and a management focus on cardiorenal comorbidity alongside selective amyloid workup. The IPA framework provides a scalable approach to characterizing cardiovascular imaging biomarkers.
Open AccessDeep Clinical Phenotyping of Perugini Grade 1 on Bone Scintigraphy: An Imaging-Phenotype Association Study
Purpose: A planar Perugini grade 1 scan is equivocal for transthyretin amyloid cardiomyopathy (ATTR-CM), has no dedicated management pathway and is biologically heterogeneous, spanning early or low-burden ATTR, AL amyloidosis and non-amyloid blood-pool activity. Rather than investigating grade 1 as a step toward amyloid confirmation, we characterized the clinical phenotype it marks and tested whether that phenotype, rather than amyloid, drives its prognosis. Methods: We studied 9,170 consecutive patients who underwent [ 99m Tc]Tc-DPD bone scintigraphy between 2010 and 2020, graded on planar imaging by blinded expert consensus. Using an imaging-phenotype association (IPA) framework analogous to genome-wide association analysis, we related Perugini grade to 1,243 clinical, laboratory, echocardiographic, cardiac magnetic resonance and ICD-10 comorbidity variables from electronic health records, adjusting for age, sex and cancer history. The outcome was a composite of heart failure hospitalization or death. Results: Grade 1 occurred in 175 (1.9%) and grade ≥2 in 142 (1.6%) patients. Grade ≥2 reproduced the canonical infiltrative ATTR phenotype, with greater septal thickness, higher extracellular volume, neuropathy and atrial fibrillation, validating the framework. Grade 1 instead marked a non-infiltrative cardiometabolic phenotype dominated by hypertension, chronic ischemic heart disease, high BMI, anemia, reduced eGFR and atrial enlargement, with low extracellular volume and septal thickness arguing against meaningful infiltration. Grade 1 carried worse outcomes than grade 0 (adjusted HR 1.30, 95% CI 1.07 to 1.59). Within grade 1, a cardiometabolic phenotype defined by hypertension, high BMI and low hematocrit, with or without chronic ischemic heart disease, identified patients whose risk matched or exceeded that of grade ≥2 (median HR 2.46 versus HR 1.76), indicating that grade 1 prognosis is driven substantially by comorbid cardiometabolic disease rather than amyloid burden. Conclusions: Perugini grade 1 is neither uniform early amyloid nor a benign artifact but a mixed-etiology, predominantly non-infiltrative cardiometabolic phenotype that carries clinically meaningful risk. A simple cardiometabolic phenotype stratifies this risk, supporting reinterpretation of grade 1 and a management focus on cardiorenal comorbidity alongside selective amyloid workup. The IPA framework provides a scalable approach to characterizing cardiovascular imaging biomarkers.
- Open Access
- 22 May 2026
- Published by Elsevier in Structural Heart
- Vol. 10 (11)
Burden and Outcome of Moderate Bivalvular Functional Regurgitation: A Large-Scale Observational Cohort Study
- 22 May 2026
- Published by Elsevier in Structural Heart
- Vol. 10 (11)
Open AccessBurden and Outcome of Moderate Bivalvular Functional Regurgitation: A Large-Scale Observational Cohort Study
- Open Access
- 7 May 2026
- Published by Elsevier in JACC: Case Reports
- Vol. 31 (25) , 108132
Long-Term Follow-Up After Dual Transcatheter Valve-in-Valve Implantation Under VA-ECMO Support
- 7 May 2026
- Published by Elsevier in JACC: Case Reports
- Vol. 31 (25) , 108132
Open AccessLong-Term Follow-Up After Dual Transcatheter Valve-in-Valve Implantation Under VA-ECMO Support
- Open Access
- 1 April 2026
- Published by Elsevier in JACC: Advances
- Vol. 5 (5) , 102705
Long-Term Outcomes of Targeted Volume Overload Management in Patients With Severe Aortic Stenosis
- 1 April 2026
- Published by Elsevier in JACC: Advances
- Vol. 5 (5) , 102705
Open AccessLong-Term Outcomes of Targeted Volume Overload Management in Patients With Severe Aortic Stenosis
- Open Access
- 17 March 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (6) , 2288
Permanent Pacemaker Implantation After TAVI and Its Association with Survival: Single-Center Cohort and Nationwide Validation
Background/Objectives: Permanent pacemaker (PM) implantation is a well-recognized complication of transcatheter aortic valve implantation (TAVI), but its long-term prognostic impact remains uncertain. To evaluate the association between PM implantation and all-cause mortality in TAVI recipients. Methods: We performed a post hoc analysis of a prospective single-center TAVI registry (2016–2020). The primary endpoint was all-cause mortality at 1 and 5 years. Cox regression and Kaplan–Meier analyses were applied. Validation was performed using the nationwide AUTHEARTVISIT claims database. Results: Among 1114 consecutive TAVI patients (mean age 81 ± 5.8 years; 49.8% female), 120 (10.8%) had a pre-existing PM (Pre-PM), and 153 (13.7%) received a new PM within 30 days post-TAVI (Post-PM). Post-PM patients were older (p = 0.006), more often male (p < 0.001), had higher Troponin T levels (p = 0.002), more pre-existing right bundle branch block (p < 0.001), and longer QRS duration (p < 0.001) compared to patients without PM. In multivariate analysis, one-year mortality was associated with Troponin T (p = 0.002) and NT-proBNP (p = 0.002) serum levels. Pre- or Post-PM status was not associated with 1-year mortality (p = 0.455, p = 975). However, Pre-PM status was independently associated with 5-year mortality (HR 1.4, 95% CI: 1.0–1.9, p = 0.03), whereas Post-PM status was not (HR 1.2, 95% CI: 0.8–1.6, p = 0.22). Findings were confirmed in the nationwide AUTHEARTVISIT cohort. Conclusions: In this large, real-world TAVI cohort with national validation, Post-PM status was not associated with mortality at 1 or 5 years. By contrast, Pre-PM identified patients at higher long-term risk, possibly reflecting underlying cardiac disease.
- 17 March 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (6) , 2288
Open AccessPermanent Pacemaker Implantation After TAVI and Its Association with Survival: Single-Center Cohort and Nationwide Validation
Background/Objectives: Permanent pacemaker (PM) implantation is a well-recognized complication of transcatheter aortic valve implantation (TAVI), but its long-term prognostic impact remains uncertain. To evaluate the association between PM implantation and all-cause mortality in TAVI recipients. Methods: We performed a post hoc analysis of a prospective single-center TAVI registry (2016–2020). The primary endpoint was all-cause mortality at 1 and 5 years. Cox regression and Kaplan–Meier analyses were applied. Validation was performed using the nationwide AUTHEARTVISIT claims database. Results: Among 1114 consecutive TAVI patients (mean age 81 ± 5.8 years; 49.8% female), 120 (10.8%) had a pre-existing PM (Pre-PM), and 153 (13.7%) received a new PM within 30 days post-TAVI (Post-PM). Post-PM patients were older (p = 0.006), more often male (p < 0.001), had higher Troponin T levels (p = 0.002), more pre-existing right bundle branch block (p < 0.001), and longer QRS duration (p < 0.001) compared to patients without PM. In multivariate analysis, one-year mortality was associated with Troponin T (p = 0.002) and NT-proBNP (p = 0.002) serum levels. Pre- or Post-PM status was not associated with 1-year mortality (p = 0.455, p = 975). However, Pre-PM status was independently associated with 5-year mortality (HR 1.4, 95% CI: 1.0–1.9, p = 0.03), whereas Post-PM status was not (HR 1.2, 95% CI: 0.8–1.6, p = 0.22). Findings were confirmed in the nationwide AUTHEARTVISIT cohort. Conclusions: In this large, real-world TAVI cohort with national validation, Post-PM status was not associated with mortality at 1 or 5 years. By contrast, Pre-PM identified patients at higher long-term risk, possibly reflecting underlying cardiac disease.